News

Tirzepatide vs Ozempic: What You're Comparing

Creator: Julian Reyes, Health Writer
Published: 2026-09-07

Ozempic is a brand of semaglutide, approved for type 2 diabetes. Tirzepatide is a different molecule with its own brands — so the comparison most people want is between two drugs, not a drug and a label.

Julian Reyes, Health Writer September 7, 2026 6 min read

A man in a navy crew-neck jumper and full-length grey trousers sits at a kitchen table peeling an orange

The short version

Ozempic is a brand of semaglutide approved for type 2 diabetes; tirzepatide is a different molecule, sold as Mounjaro for diabetes and Zepbound for obesity. The comparison people mean is usually molecule against molecule.
SURMOUNT-5 (751 adults with obesity, no diabetes, 72 weeks) reported 20.2% average body-weight loss on tirzepatide against 13.7% on semaglutide — but that semaglutide arm used 1.7 or 2.4 mg, above Ozempic's 2 mg label maximum.
SURPASS-2 (1,879 adults with type 2 diabetes, 40 weeks) used semaglutide 1 mg, an Ozempic dose: tirzepatide lowered HbA1c by 0.15 to 0.45 points more and body weight by 1.9 to 5.5 kg more.
Mounjaro's label, revised 08/2026, now includes reducing major cardiovascular events in adults with type 2 diabetes at high risk. That trial compared tirzepatide with another GLP-1 drug rather than a placebo, and it was non-inferior, not superior.
Promise dispenses tirzepatide and semaglutide as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved.

Tirzepatide vs Ozempic is a comparison between two different kinds of thing, which is most of why it gets confusing. Tirzepatide is a molecule — the active drug inside Mounjaro and Zepbound. Ozempic is a brand name, one of several products built around a different molecule called semaglutide.

So the question underneath the question is usually this: how do tirzepatide and semaglutide compare, and does the Ozempic part change the answer? It does, in one specific way. The dose.

Two trials have put the two molecules directly against each other, and tirzepatide came out ahead on the numbers in both. Only one of them used a dose Ozempic actually goes up to.

Tirzepatide vs Ozempic: what each name stands for

Tirzepatide is a once-weekly injection that works on two of the body's own gut hormones at once — GLP-1 and GIP, the signals that nudge the pancreas to release insulin after a meal and tell the brain you have eaten. Semaglutide works on one of those two, GLP-1.

Ozempic is Novo Nordisk's semaglutide product for type 2 diabetes. Wegovy is the same molecule at a higher dose, for weight management. Rybelsus is the tablet.

Tirzepatide's brands split the same way: Mounjaro for type 2 diabetes, Zepbound for obesity and for obstructive sleep apnea.

Name	What it is	What it covers
Tirzepatide	The molecule (GIP + GLP-1)	The active drug in Mounjaro and Zepbound
Semaglutide	The molecule (GLP-1)	The active drug in Ozempic, Wegovy and Rybelsus
Ozempic	A brand of semaglutide	Type 2 diabetes; label maximum 2 mg once weekly
Mounjaro	A brand of tirzepatide	Type 2 diabetes; label maximum 15 mg once weekly

If it's the brand-versus-molecule tangle that's tripping you up, is semaglutide the same as Ozempic takes that apart on its own.

The two trials that put them head to head

The first was SURPASS-2, published in 2021: 1,879 adults with type 2 diabetes, followed for 40 weeks. One group got tirzepatide at 5, 10 or 15 mg. The other got semaglutide at 1 mg — squarely an Ozempic dose.

Average blood sugar, measured as HbA1c (a rolling three-month average), fell 2.01 to 2.30 points across the tirzepatide doses against 1.86 points on semaglutide. Average weight fell a further 1.9 to 5.5 kg on tirzepatide, depending on the dose (Frías et al., NEJM 2021).

The second was SURMOUNT-5, published in 2025: 751 adults with obesity and no diabetes, followed for 72 weeks. Tirzepatide averaged 20.2% of body weight lost, semaglutide 13.7%. Waist circumference came down 18.4 cm against 13.0 cm (Aronne et al., NEJM 2025).

That second trial is the one everyone quotes, and it's also where the Ozempic framing quietly breaks. Its semaglutide arm used 1.7 or 2.4 mg — the Wegovy range. Ozempic's label stops at 2 mg. So SURMOUNT-5 is closer to tirzepatide against Wegovy, and SURPASS-2 is the closer thing to tirzepatide against an Ozempic dose.

Both numbers are averages, and an average is a crowd rather than a person. Our fuller molecule-to-molecule breakdown — tirzepatide vs semaglutide — walks through the rest of the numbers.

What Ozempic is approved for, and what it isn't

Here is where a lot of comparisons go wrong without anyone noticing. Ozempic is FDA-approved for type 2 diabetes, not for weight loss.

Its prescribing information, revised 05/2026, lists three uses: blood-sugar control in adults with type 2 diabetes; lowering the risk of heart attack, stroke and cardiovascular death in adults who have type 2 diabetes and established heart disease; and slowing kidney decline in adults with type 2 diabetes and chronic kidney disease (Ozempic prescribing information).

Weight management belongs to Wegovy's label. Plenty of people take Ozempic and lose weight along the way. But if what you mean is tirzepatide for weight loss versus Ozempic for weight loss, you are comparing against a product whose label doesn't cover that use.

Mounjaro's new heart indication

As of September 6, 2026, the day this article was written, the newest change in this comparison sits on the tirzepatide side. Mounjaro's US prescribing information, revised 08/2026, now carries a second indication: reducing the risk of major cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk of them (Mounjaro prescribing information). The manufacturer announced it on August 28, 2026 (Lilly release).

What that was built on matters. SURPASS-CVOT enrolled 13,299 adults who had both type 2 diabetes and established artery disease, and followed them for a median of about four years. Tirzepatide wasn't tested against a dummy injection but against dulaglutide, another once-weekly GLP-1 drug that already had heart data behind it. Major events happened in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group: a hazard ratio of 0.92, which cleared the bar for not worse but not the bar for better (Nicholls et al., NEJM 2025).

Ozempic's heart indication came by a different route. SUSTAIN-6 compared semaglutide with placebo in 3,297 adults over two years, and major events happened in 6.6% of the semaglutide group against 8.9% on placebo, a hazard ratio of 0.74 (Marso et al., NEJM 2016).

Two things follow from that. The two heart indications are not the same claim, because the comparison behind each one was different. And neither indication travels to a compounded version — a label indication belongs to the product that ran the trial. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision sits between you and your doctor.

Side effects run closer than the weight numbers do

In SURPASS-2, where the semaglutide dose was the Ozempic-range 1 mg, nausea affected 17% to 22% of the tirzepatide groups and 18% of the semaglutide group. Diarrhea, 13% to 16% against 12%. Vomiting, 6% to 10% against 8%. Serious adverse events, 5% to 7% against 3%.

Read plainly: gastrointestinal-event rates were in a similar range, but neither treatment was lower for every symptom and dose. Tirzepatide side effects covers what that tends to look like week by week.

What changes when the version is compounded

Promise doesn't dispense Ozempic or Mounjaro. Both molecules here are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here — tirzepatide with vitamin B12, and semaglutide with vitamin B12 — are not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness or quality.

In practice that means you're comparing a preparation made by a licensed pharmacy for one patient on a prescription against a mass-manufactured branded product. Lower price, different thing — not a discount version of the same box. Compounded semaglutide explains how those preparations are made and who oversees them.

Either way it's a prescription route. A licensed provider reviews every request against your history and prescribes only if they judge it appropriate, and not everyone qualifies.

Which question you're actually asking

Three people type "tirzepatide vs ozempic" and mean three different things.

If you mean which molecule moved weight further in trials, that was tirzepatide, in both head-to-head studies, at 40 weeks and at 72.

If you mean should I switch, no table answers that. It turns on your blood sugar, your other medicines, what you've tolerated before and what you're being treated for.

And if you mean which one can I actually get, Ozempic and Mounjaro are branded products filled at a retail pharmacy, usually with insurance somewhere in the story. A compounded prescription is a different route, with a different price and a different set of trade-offs.

Common questions

Is Ozempic the same as tirzepatide?

No. Ozempic contains semaglutide, which acts on one gut hormone receptor, GLP-1. Tirzepatide is a separate molecule that acts on two, GLP-1 and GIP, and it is sold under the brand names Mounjaro and Zepbound rather than Ozempic. They are made by different companies, carry different labels and were studied in different trial programs.

Which works better for weight loss, tirzepatide or Ozempic?

In the two trials that compared the molecules directly, tirzepatide produced the larger average result. SURMOUNT-5 reported 20.2% average body-weight loss on tirzepatide against 13.7% on semaglutide over 72 weeks. One caveat matters: that semaglutide arm used Wegovy-range doses, above Ozempic's 2 mg maximum, and Ozempic's own label does not cover weight management.

Is compounded tirzepatide FDA-approved?

No. FDA-approved tirzepatide products exist — Mounjaro and Zepbound — but the compounded formulation offered here is not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness or quality. A licensed provider may still prescribe a compounded formulation when they judge it appropriate for the patient in front of them.

Do tirzepatide and Ozempic have the same side effects?

They are close. In SURPASS-2, which used the Ozempic-range 1 mg semaglutide dose, nausea affected 17% to 22% of tirzepatide participants and 18% of semaglutide participants, with diarrhea and vomiting also in a similar band. Serious adverse events were reported in 5% to 7% of tirzepatide participants and 3% of semaglutide participants. Most stomach effects clustered while the dose was rising.

Does Mounjaro's new heart indication apply to compounded tirzepatide?

It does not. A label indication belongs to the specific product that ran the trial and was reviewed on it, so the cardiovascular wording added to Mounjaro in August 2026 does not extend to a compounded preparation. The underlying trial also compared tirzepatide with another GLP-1 drug rather than a placebo, and found it non-inferior rather than superior.

Can you switch from Ozempic to tirzepatide?

People do, and it is a clinical decision rather than a swap you arrange yourself. A prescriber weighs why you started, how your blood sugar or weight has responded, what side effects you have had and what else you take. Doses do not translate across the two molecules, so any change starts a new titration from the beginning.